Tagged with clinical trials

Taiwan Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US, following ten completed clinical studies. President Antony Hsu outlines the science behind selective adipocyte apoptosis, the regulatory strategy behind the…

USA Dr Carlos Prada, Director of the Edwards Family Division of Genetics and Rare Diseases at Ann & Robert H. Lurie Children’s Hospital of Chicago, discusses how earlier diagnosis, coordinated care pathways, and emerging therapeutic modalities are reshaping outcomes for children and families. From newborn screening and multidisciplinary follow-up to the…

Taiwan In 2024, Taipei Medical University reached a defining milestone. President Mai-Szu Wu oversaw a full digital transformation linking seven affiliated medical institutions and more than 3,000 beds into a unified data platform, creating a foundation for large-scale research, AI applications, and faster clinical-trial operations. This momentum has now extended nationwide…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$ 888 million AI-driven oncology collaboration with Servier. BioRay and Simcere Zaiming filed for Hong Kong IPOs to advance their pipelines,…

Korea Korea, already one of the world’s top clinical research destinations, is looking to boost the efficiency of its clinical trial processes even further by launching K-CThub, a one-stop digital platform for trial sponsors.*     The explosion in popularity of Korean culture over the last two decades has catapulted Korea into…

Taiwan Jayashri Kulkarni Managing Director of Johnson & Johnson Taiwan, brings 27 years of experience across pharmaceuticals and medical technology in Asia Pacific. Since assuming her Taiwan role , she has focused on outcome-based healthcare, patient advocacy, and leadership development, bringing a perspective that bridges emerging market innovation with healthcare system…

Taiwan As President of the Taiwan Clinical Research Association (TCRA), Tina Sun brings 25 years of pharmaceutical industry experience to bear on the evolution of Taiwan’s clinical research ecosystem. This interview explores TCRA’s pivotal role in harmonising regulatory frameworks, fostering cross-stakeholder collaboration, and positioning Taiwan as a competitive clinical trials hub…

Tags: USA Manisha Balwani is Chief of the Division of Medical Genetics and Genomics at Icahn School of Medicine at Mount Sinai, where she leads programs spanning genetic screening, diagnosis, clinical trials, and treatment across the lifespan. In this interview, she discusses how Mount Sinai supports rare disease patients from early identification…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered royalties. Biokin proposes RMB 10B in debt financing to fuel innovation, highlighted by its advanced ADC programs. Insilico Medicine successfully…

Brazil Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology transfer agreements is bolstering local manufacturing capabilities and helping these companies scale the value chain. Multinationals – with the right…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX debut, and Juncell’s Hong Kong IPO filing targeting China’s first TIL therapy. Biocytogen listed on Shanghai’s STAR Market for its…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech, and Proviva Therapeutics securing US$30M for its PD-1/IL-2 prodrug. Clinical developments feature Pfizer’s zavegepant nasal spray filing in China, Rhegen’s…